Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Table 1 Patient demographics and disease characteristics at UPA initiation

Parameter	FAS (N = 1701)
Age (years), mean (SD)	56.9 (12.4)
Sex, female, n (%)	1359 (79.9)
Race, n (%)
White	1184 (69.6)
Asian	85 (5.0)
Arabic	75 (4.4)
Other^a	40 (2.4)
BMI (kg/m²), mean (SD)^b	26.9 (5.5)
RA duration from diagnosis, years, mean (SD)^c	10.1 (9.1)
Smoking status, n (%)^d
Current	316 (18.6)
Former	354 (20.8)
Never	1028 (60.5)
Vaccination status, n (%)
SARS-CoV-2	836 (49.1)
BCG^e	616 (37.5)
Streptococcus pneumoniae	353 (20.8)
Seasonal influenza	350 (20.6)
Varicella zoster	99 (5.8)
Erosions on X-ray, n (%)	710 (41.7)
RF and/or ACPA positive, n (%)^f	545 (77.6)
Disease activity, mean (SD)
Swollen joint count	5.7 (5.20)
Tender joint count	8.1 (6.4)
DAS28(CRP)	4.6 (1.2)
CDAI	26.5 (12.6)
SDAI	28.2 (14.1)
Presence of ≥ 1 cardiovascular risk factor, n (%)^g	1058 (62.2)
Patients initiating UPA in combination with csDMARDs, n (%)	878 (51.6)
Any concomitant medication, n (%)^h	1312 (77.1)
Corticosteroidsⁱ	734 (43.2)
NSAIDs	351 (20.6)
Any prior therapies^j, n (%)^k	1523 (90.0)
≥ 1 csDMARD^l	1203 (79.0)
≥ 1 biologic DMARD^l	979 (64.3)
≥ 1 targeted synthetic DMARD^l	276 (18.1)

^aIncluding Black or African American, Indian, American Indian, or Alaska Native, and multiple. ^bOf 1646 patients with available data, 43 (2.6%) were underweight (BMI < 18.5), 617 (37.5%) were normoweight (BMI 18.5–24.9), 577 (35.1%) were overweight (BMI 25.0–29.9), and 409 (24.8%) were obese (BMI ≥ 30). ^cn = 1687. ^dn = 1698. ^en = 1644. ^fPatients with ≥ 1 positive result for either RF or ACPA; n = 702. ^gHistory of hypertension, diabetes mellitus, high-density lipoprotein cholesterol ≤ 40 mg/dL in ≥ 1 measurement before enrollment, low-density lipoprotein cholesterol ≥ 130 mg/dL in ≥ 1 measurement before enrollment, and current/former tobacco/nicotine use. ^hMethotrexate: n = 706 (41.5%) patients. ⁱThe mean equivalent dose of prednisone during the first week was 8 mg/day (n = 461), and 393 patients (85.2%) received ≥ 5 mg/day. Not ongoing. ^kn = 1692. ^lPatients may be counted multiple times between type of RA therapies
ACPA anti-citrullinated protein antibody, BCG bacillus Calmette-Guérin, BMI body mass index, CDAI clinical disease activity index, csDMARD conventional synthetic DMARD, DAS28(CRP) disease activity score in 28 joints using C-reactive protein, DMARD disease-modifying antirheumatic drug, FAS full analysis set, NSAID non-steroidal anti-inflammatory drug, RA rheumatoid arthritis, RF rheumatoid factor, SD standard deviation, SDAI simplified disease activity index, UPA upadacitinib

ISSN: 1478-6362